BioNet News, Pertussis 17 Jun 2022 Etude Pertagen® 2xÉTUDE SUR PERTAGEN®, UN NOUVEAU VACCIN CONTRE LA COQUELUCHE Statut En cours de recrutement. La coqueluche circule largement chez les jeunes, qui jouent un rôle de réservoir et transmettent… Supachai
Biotech News 05 May 2022 Thailand’s first Covid-19 vaccine waits for approval from local FDA Better late than never. Thailand’s first Covid-19 vaccine, ChulaCov19, has shown impressive results in the first and second rounds of… Supachai
Biotech News 07 Apr 2022 New crop of COVID-19 mRNA vaccines could be easier to store, cheaper to use If approved, they could bring the pandemic’s star vaccine technology to more of the world The two COVID-19 vaccines based… Supachai
BioNet News, Covid-19, Press Releases 21 Mar 2022 Technovalia, Sypharma and BioNet announce the establishment of Genetis, the first Australian Vaccine Development and Manufacturing Hub for mRNA, DNA and recombinant vaccines. Supachai
BioNet News, Pertussis 26 Feb 2022 Pharmaniaga And Thailand’s BioNet Group Collaborate In Vaccine R&D Pharmaniaga Berhad is looking to collaborate and partner with Thailand’s BioNet Group for vaccine research and development (R&D) and Bio-Innova… Supachai
BioNet News, Covid-19 01 Feb 2022 BioNet earns up to $16.9M from CEPI for studies, production and analysis of variant-proof SARS-CoV-2 vaccine Drawing from a $200 million program meant to stimulate the development of vaccines with broad betacoronavirus protection, the Coalition for… Supachai
BioNet News, Covid-19 26 Jan 2022 CEPI partners with BioNet to expand variant-proof vaccine programme OSLO, Norway, 25 January 2022: CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the latest award under its $200m programme, launched… Supachai
BioNet News, Covid-19, Press Releases 18 Jan 2022 COVALIA study update: Interim Safety Results from needle-free SARS-CoV2 DNA vaccine phase 1 trial Melbourne 17 January 2022 –Technovalia, an Australian biotech vaccine developer today announced the interim safety results of the ongoing phase… Supachai
BioNet News, Pertussis, Publication 06 Dec 2021 A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age Background: A phase 2 randomized-controlled safety and immunogenicity trial evaluating different doses of recombinant acellular pertussis vaccine containing genetically-inactivated pertussis… Supachai
BioNet News, Covid-19 16 Nov 2021 Vaccine partnership results in optimized mRNA process, says BioNet BioNet’s product development of genetic vaccine know-how integrated with BIA’s chromatographic columns for mRNA purification has produced a high-yield mRNA… Supachai